Skip to main content

NICE TAs

04/05/2020
TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
04/05/2020
TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
04/05/2020
TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
04/05/2020
TA442: Ixekizumab for treating moderate to severe plaque psoriasis
04/05/2020
TA479: Reslizumab for treating severe eosinophilic asthma
04/05/2020
TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
04/05/2020
TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
04/05/2020
TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
04/05/2020
TA463: Cabozantinib for previously treated advanced renal cell carcinoma
04/05/2020
TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
04/05/2020
TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
04/05/2020
TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
01/05/2020
TA456: Ustekinumab for moderately to severely active Crohn's disease after previous treatment
01/05/2020
TA448: Etelcalcetide for treating secondary hyperparathyroidism
01/05/2020
TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
01/05/2020
TA487: Venetoclax for treating chronic lymphocytic leukaemia
01/05/2020
TA443: Obeticholic acid for treating primary biliary cholangitis
01/05/2020
TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
01/05/2020
TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
01/05/2020
TA466: Baricitinib for moderate to severe rheumatoid arthritis
Follow AWTTC: